Key Highlights

  • Q2 2026 Revenue rose 13% to $1.308 billion; non-GAAP gross Margin rose to 64.1% from 60.1% (Jul 30 release).
  • 2026 revenue guidance is now $5.18-$5.25 billion, with non-GAAP Operating Margin of 23.5%-24% and adjusted EBITDA margin of 31.5%-32%.
  • On Sep 14, CFO Jereme Sylvain added the COO role, overseeing global operations and quality.
  • DexCom ended June with $1.95 billion in cash and marketable securities and repurchased about $600 million of stock during the quarter.

DexCom (NASDAQ:DXCM) raised its 2026 outlook on July 30 because its second quarter combined double-digit sales growth with a sharp jump in profitability, and management credited part of the margin gain to the shift of US users onto its 15-day G7 sensor. The glucose-monitoring company reported revenue of $1.308 billion, up 13% from a year earlier, and lifted its full-year guidance for revenue, gross margin, operating margin and adjusted EBITDA margin.

The new revenue range is $5.18 billion to $5.25 billion, which the company said implies growth of about 11% to 13%. The previous range was $5.16 billion to $5.25 billion, so the upgrade raised the low end and the midpoint rather than the ceiling. Non-GAAP gross margin guidance is now about 64%, and non-GAAP operating margin guidance is 23.5% to 24%.

DexCom has since reshaped its leadership. On September 14 it promoted Chief Financial Officer Jereme Sylvain to also serve as Chief Operating Officer, with oversight of global operations and quality teams, which are central to executing the G7 15-day transition at scale.

What the G7 15 Day Changed

The G7 15 Day extends sensor wear beyond the standard G7's roughly 10-day life. That means fewer sensors per patient each year and, for DexCom, better unit economics. Gross margin improved about 400 basis points year over year, driven by Manufacturing efficiencies and the G7 15-day system transition.

DexCom is on track to move nearly 50% of its US customers to the 15-day system by year-end, and its Net Promoter Scores have improved for three consecutive quarters. Management also expects some margin pressure later this year as manufacturing ramps up at its Ireland plant, which is one reason the gross margin guide stops at about 64%, roughly in line with the second-quarter level.

Second-Quarter Results in Detail

US revenue grew 11% to $933.4 million, and international revenue rose 19% to $375.0 million, or 16% on an organic basis. Organic revenue, which excludes currency and acquired non-CGM sales, grew 12% overall.

GAAP gross margin widened to 63.4% from 59.5%, and non-GAAP gross margin reached 64.1% versus 60.1% a year earlier. GAAP Operating Income rose to $318.3 million, or 24.3% of revenue, from $212.6 million. Non-GAAP operating margin expanded 590 basis points to 25.1%.

GAAP Net Income rose to $249.1 million, or $0.64 per diluted share, from $179.8 million, or $0.45. Non-GAAP Earnings reached $0.70 per share versus $0.48. Adjusted EBITDA was $421.3 million, or 32.2% of revenue.

The Balance Sheet stayed strong. DexCom ended June with $1.95 billion in cash, cash equivalents and marketable securities, and an undrawn revolving Credit facility. Free Cash Flow topped $600 million in the first half, and the company repurchased about $600 million of stock in the quarter.

Growth Drivers Beyond the Sensor

DexCom's release highlighted three strategic developments in the quarter. It held a 2026 Investor Day that set a new long-term financial outlook through 2030. It reported positive results from the CONNECT randomized controlled trial in people with type 2 diabetes not using insulin. And it relaunched its Stelo over-the-counter app with AI-driven insights and food logging.

The type 2 non-insulin population is the largest untapped market for continuous glucose monitors (CGMs). CONNECT showed a 0.9 percentage point improvement in A1c versus the control group, and DexCom has secured coverage for all people with diabetes at the four largest US commercial pharmacy benefit managers. That gives more than 7 million type 2 non-insulin patients access. The FDA also selected DexCom for its TEMPO digital health device pilot.

Chief Executive Jake Leach said in the release that the quarter's results and the CONNECT trial "reinforce our confidence in the path ahead" and position the company to deliver on its long-range plan.

Leadership Reshuffle and Competitive Pressure

In the September 14 announcement, Leach called Sylvain "an exceptional leader," citing his operational discipline and customer focus. Sylvain joined DexCom in 2018 and has been CFO since 2021. The promotion fills a vacancy created when Leach, the former operating chief, became CEO. A related Form 8-K made the appointment effective September 14, consolidating oversight of operations, quality and finance under one executive.

Competition remains intense. Abbott (NYSE:ABT)'s FreeStyle Libre Franchise is DexCom's main rival in both insulin-using and broader type 2 markets. Both companies are also pushing into over-the-counter wellness sensors. Pricing, pharmacy-channel access and sensor accuracy all remain contested.

Risks to Watch

  • Manufacturing and quality: DexCom received an FDA warning letter in 2025 related to manufacturing. Putting quality under Sylvain's direct oversight shows it remains a priority as the Ireland plant ramps up.
  • Margin durability: management has flagged ramp-up costs in Ireland, and the 15-day conversion is only about halfway through in the US.
  • Currency and reimbursement: the company expects about a $15 million foreign-exchange headwind to international revenue in the second half. Coverage for non-insulin type 2 patients also still depends on payer decisions.
  • Guidance range: the $5.25 billion ceiling was left unchanged, so upside depends on execution within an unchanged top end.

Tracking the Pace of the 15-Day Conversion

DexCom has not yet announced its third-quarter reporting date. It has typically reported in late October, and it released second-quarter results on July 30. Investors will track US conversion to the 15-day G7 against the roughly 50% year-end target, and whether gross margin holds near 64% as Irish production scales. They will also watch for signs that CONNECT and the broader pharmacy benefit manager coverage are lifting new type 2 patient starts.

Execution under Sylvain's combined finance and operations remit will get close scrutiny, especially on quality and supply. With the midpoint of revenue guidance and every margin target raised in July, the fourth-quarter setup will show whether the 15-day sensor can keep delivering both growth and profitability.